Ocular manifestations of HIV infection at Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa
DOI:
https://doi.org/10.7196/SAMJ.2023.v113i10.950Keywords:
HIV, Eye, Ocular disease, Cataract, HIV retinopathy, Antiretroviral Therapy, Ocular manifestations of HIVAbstract
Background. The pattern of HIV-associated eye disease has changed with ongoing advancements in highly active antiretroviral therapy (HAART). HIV-infected individuals now live longer, enabling us to observe the long-term effects of HIV and HAART on the eye. There are few recent studies on HIV-related ocular disease in sub-Saharan Africa.
Objectives. To describe the ocular manifestations of HIV in patients attending the Nthabiseng HIV clinic at Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa.
Methods. A cross-sectional study was conducted in 2021 and 2022 using convenience sampling of patients at the HIV clinic. The participants’ clinical history was taken, their files were reviewed, and they underwent ocular examination. Correlation between eyes was managed by taking disease in one eye as the presence of disease in the participant. Descriptive statistics were used to summarise participant characteristics. Univariate and multivariate logistic regression models were used to assess the odds ratio (OR) of developing HIV-associated ocular diseases, and a p-value of <0.05 was used to define statistical significance.
Results. There were 182 participants (139 females and 43 males), with a mean (standard deviation) age of 48.9 (10.6) years. The most common anterior segment diagnoses were conjunctival microangiopathy (34.6%), pinguecula (31.3%) and cataracts (30.2%), while the most common posterior segment finding was peripheral retinal scarring with features in keeping of previous cytomegalovirus retinitis (24.2%). Notably, only 1.1% of patients had HIV retinopathy. A CD4 count <200 cells/μL showed an increased OR for cataracts (OR 4.24; p=0.003) and any anterior segment diagnoses (OR 10.05; p=0.029), while a CD4 count ≥200 cells/μL showed an increased risk of conjunctival microangiopathy (OR 2.14; p=0.017).
Conclusion. With the advent of HAART, ocular manifestations of HIV are changing and the incidence of severe ocular opportunistic infections and HIV retinopathy has decreased precipitously. Although this study has shown that patients with a CD4 count <200 cells/μL are at increased risk of developing anterior ocular manifestations of HIV, including cataracts, these diseases are relatively innocuous or easily treatable. Routine ocular screening of HIV patients seems to be substantially less important now than it was in the pre-HAART era.
References
Cunningham ET, Margolis TP. Ocular manifestations of HIV infection. N Engl J Med 1998;339(4):236- 244. https://doi.org/10.1056/NEJM199807233390406
Govender P, Hansraj R, Naidoo KS, Visser L. Ocular manifestations of HIV/AIDS: A literature review* (Part 1). S Afr Optom 2010;69(4):193-199. https://doi.org/10.4102/aveh.v69i4.141
Govender P, Hansraj R, Naidoo KS, Visser L. Ocular manifestations of HIV/AIDS: A literature review (Part 2)*. S Afr Optom 2011;70(2):81-88. https://doi.org/10.4102/aveh.v70i2.97
Moraes HV. Ocular manifestations of HIV/AIDS. Curr Opin Ophthalmol 2002;13(6):397-403. https:// doi.org/10.1097/00055735-200212000-00010
Sugar EA, Jabs DA, Ahuja A, Thorne JE, Danis RP, Meinert CL. Incidence of cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol 2012;153(6):1016-1024.e5. https:// doi.org/10.1016/j.ajo.2011.11.014
Hoover DR, Peng Y, Saah A, et al. Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression. Arch Ophthalmol 1996;114(7):821-827. https://doi. org/10.1001/archopht.1996.01100140035004
Accorinti M, Pirraglia MP, Corradi R, Corsi C, Fabiani C, Pivetti-Pezzi P. Changing patterns of ocular manifestations in HIV seropositive patients treated with HAART. Eur J Ophthalmol 2006;16(5):728- 732. https://doi.org/10.1177/112067210601600511
Sudharshan S, Nair N, Curi A, Banker A, Kempen JH. Human immunodeficiency virus and intraocular inflammation in the era of highly active antiretroviral therapy – an update. Indian J Ophthalmol 2020;68(9):1787-1798. https://doi.org/10.4103/ijo.IJO_1248_20
Osler M, Hilderbrand K, Goemaere E, et al. The continuing burden of advanced HIV disease over 10 years of increasing antiretroviral therapy coverage in South Africa. Clin Infect Dis 2018;66(Suppl 2):S118-S125. https://doi.org/10.1093/cid/cix1140
Schaftenaar E, van Gorp ECM, Meenken C, et al. Ocular infections in sub-Saharan Africa in the context of high HIV prevalence. Trop Med Int Health 2014;19(9):1003-1014. https://doi.org/10.1111/ tmi.12350
Schaftenaar E, Khosa NS, Baarsma GS, et al. HIV-infected individuals on long-term antiretroviral therapy are at higher risk for ocular disease. Epidemiol Infect 2017;145(12):2520-2529. https://doi. org/10.1017/S0950268817000978
Saini N, Hasija S, Kaur P, Kaur M, Pathania V, Singh A. Study of prevalence of ocular manifestations in HIV positive patients. Nepal J Ophthalmol 2019;11(21):11-18. https://doi.org/10.3126/nepjoph. v11i1.25411
Otwombe K, Dietrich J, Laher F, et al. Health-seeking behaviours by gender among adolescents in Soweto, South Africa. Glob Health Action 2015;8:25670. https://doi.org/10.3402/gha.v8.25670
Pathai S, Lawn SD, Weiss HA, Cook C, Bekker LG, Gilbert CE. Increased ocular lens density in HIV-infected individuals with low nadir CD4 counts in South Africa: Evidence of accelerated aging. J Acquir Immune Defic Syndr 2013;63(3):307-314. https://doi.org/10.1097/QAI.0b013e31828ad759
Jabs DA, van Natta ML, Holbrook JT, et al. Longitudinal study of the ocular complications of AIDS: 1. Ocular diagnoses at enrollment. Ophthalmology 2007;114(4):780-786. https://doi.org/10.1016/j. ophtha.2006.11.008
Rahangdale L, Cates M, Potter J, et al. Integrase inhibitors in late pregnancy and rapid HIV viral load reduction. Am J Obstet Gynecol 2016;214(3):385.e1-7. https://doi.org/10.1016/j.ajog.2015.12.052
Rasmussen LD, Kessel L, Molander LD, et al. Risk of cataract surgery in HIV-infected individuals:
A Danish nationwide population-based cohort study. Clin Infect Dis 2011;53(11):1156-1163. https://doi.org/10.1093/cid/cir675
Saadouli D, Ammari L, Ben Mansour K, et al. Ocular manifestations of people living with HIV in Tunisia. South Afr J HIV Med 2021;22(1):1193. https://doi.org/10.4102/sajhivmed.v22i1.1193
Acharya PK, Venugopal KC, Karimsab DP, Balasubramanya S. Ocular manifestations in patients with HIV infection/AIDS who were referred from the ART Centre, Hassan, Karnataka, India. J Clin Diagn Res 2012;6(10):1756-1760. https://doi.org/10.7860/JCDR/2012/4738.2637
Hsu W-M, Chiou S-H, Chen SS-L, et al. The HIV RNA levels of plasma and ocular fluids in AIDS patients with ophthalmic infections. Ophthalmologica 2004;218(5):328-332. https://doi. org/10.1159/000079475
Jabs DA, van Natta ML, Holland GN, Danis R. Cytomegalovirus retinitis in patients with AIDS after initiating antiretroviral therapy. Am J Ophthalmol 2017;174:23-32. https://doi.org/10.1016/j. ajo.2016.10.011
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Dr Ibraaheem Ismail, Dr Michelle Venter, Dr Sarah Ismail, Dr Naseer Ally
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.
